Table 2

Subgroup analyses of risk of herpes zoster among statin users

SubgroupOR (95% CI)No of studies I2 (%)P(heterogeneity)
Study type
 Case control1.15 (1.03 to 1.29)396<0.00
  Cohort1.19 (1.11 to 1.27)3740.02
Study region
  Asia1.26 (1.22 to 1.30)3110.33
  North America1.08 (0.95 to 1.23)2580.12
  Europe1.13 (1.11 to 1.15)1NANA
Female percentage
  ≥50%1.19 (1.13 to 1.26)593<0.00
  <50%0.98 (0.82 to 1.17)1NANA
Participants
  ≥200 thousand1.13 (1.11 to 1.15)201.00
  <200 thousand1.22 (1.14 to 1.30)4700.02
Mean age
  ≥60 years1.16 (1.09 to 1.242700.07
  <60 years1.18 (1.08 to 1.29)494<0.00
Quality of study*
 High 1.18 (1.07 to 1.30)2810.02
  Moderate1.17 (1.07 to 1.28)492< 0.00
  • *A total score of 4–6 was considered moderate quality, and 7–9 was deemed high quality.